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A B S T R A C T
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. With dramatic improvements in
survival observed since the 70’s, it progressively became evident that the long-term survivors faced late mor-
bidity, late mortality and psychosocial troubles.
In 2010, the EORTC developed the retrospective 58LAE study in order to evaluate the long-term outcome of
the 2621 eligible childhood ALL survivors enrolled between 1971 and 1998.
The ﬁrst sub-project project showed that ETV6-RUNX1 positive patients had better long-term outcome and
had speciﬁc sensitivities to treatments. The second sub-project showed that omission of cranial radiotherapy did
not increase the risk of relapse and was associated with a higher incidence of second neoplasms and late toxi-
cities in medium and high-risk patients, without central nervous system (CNS) involvement. The third sub-
project identiﬁed hematopoietic stem cell transplantation, cranial radiotherapy and having a relapse as risk
factors for worse socio-economic outcome. Finally, the fertility status of the survivors was also evaluated.
The 58LAE project has raised several challenges when translated into the “real-life” setting, which include the
diﬃculties of following childhood cancer survivors throughout their transition to adult life; the statistical
analysis of a cohort of patients treated in multiple clinical trials and along diﬀerent years; the need for combining
diﬀerent approaches to gather suﬃcient quality patient data; and the challenge of overcoming the healthcare
administrative and regulatory obstacles.
New ways of addressing survivorship studies are needed to address these challenges.
1. The scientiﬁc background
Acute lymphoblastic leukemia (ALL) is the most common childhood
cancer. The introduction of intensive combinations of chemotherapy,
including the use of stem cell transplantation, the reﬁnement of risk-
based stratiﬁcation and the improvement of supportive care resulted in
dramatic increase in survival since the 70′s. Five-year overall survival
progressively raised from 20% in 1970–85% in children (< 14 years)
and 62% in adolescents (15–19 years) with contemporary therapy. In
parallel, it progressively became evident that the long-term survivors
faced late morbidity, late mortality and psychosocial troubles due to
ALL and its treatments leading to a shift paradigm from survival to life
of quality.
Beside large cohorts of childhood cancer survivors treated with
various therapeutic protocols, the European Organization for Research
and Treatment of Cancer Children’s Leukemia Group (EORTC CLG)
initiated a speciﬁc long-term outcome evaluation of childhood ALL
survivors homogeneously treated in EORTC studies. A long-term update
https://doi.org/10.1016/j.jcpo.2018.02.006
Received 6 November 2017; Received in revised form 8 February 2018; Accepted 9 February 2018
⁎ Corresponding author.
E-mail addresses: caroline.piette@eortc.be, caroline.piette@chrcitadelle.be (C. Piette).
Journal of Cancer Policy 15 (2018) 82–86
Available online 12 February 2018
2213-5383/ © 2018 Elsevier Ltd. All rights reserved.
T
of speciﬁc randomized questions, taking into account both the long-
term survival and the late adverse eﬀects was indeed needed in order to
conﬁrm some controversial therapeutic choices, such as the indications
of cranial irradiation in childhood ALL. Long-term updates were also
warranted in case late relapses were suspected, such as in the ETV6-
RUNX1 positive or hyperdiploid ALL subgroups. Furthermore, late
follow-up results are useful to orientate speciﬁc therapeutic choices and
further adapt the risk-directed therapy in future protocols. Finally, they
were necessary to set up speciﬁc and standardized long-term follow-up
for childhood ALL patients treated in BFM-like studies.
In 2010, the EORTC CLG developed a “Late Adverse Eﬀects” project
called “EORTC 58LAE project” (“Assessment of the long-term outcome of
childhood ALL patients enrolled in EORTC Children's Leukemia Group trials
between 1971 and 1998”).
The aims of this retrospective project were to assess the long-term
outcome of childhood ALL patients enrolled in EORTC CLG trials be-
tween 1971 and 1998:
- Long-term vital status: evaluation of the long-term survival and of
the incidence of death due to ALL progression/relapse, acute toxi-
city, late adverse eﬀects or second malignant neoplasms (SMN).
- Medical data: assessment of the long-term disease status, the in-
cidence and the types of late adverse eﬀects and SMN, and com-
parison between randomized treatment arms or treatment groups.
- Socioeconomic data: evaluation of the marital status, the education
level and work and comparison between randomized treatment
arms or treatment groups and with the general population.
- Quality of Life (QOL) data: study of the QOL level of patients of 18
years or older at the time of the 58LAE study enrollment and com-
parison with the general population, assessment of the impacts of
the treatment type, the occurrence of late adverse eﬀects, the oc-
currence of SMN and/or the socioeconomic status on QOL and
health-related QOL (HRQOL).
2. The project
Patients with ALL or lymphoblastic lymphoma who were enrolled as
children (less than 18 years old at diagnosis) in EORTC CLG studies
between 1971 and 1998 (EORTC studies 58741, 58831/2 and 58881)
were eligible in the 58LAE project. For the socioeconomic and QOL
evaluations, eligible patients were those eligible in the EORTC study
58LAE and 18 years or older at the time of the evaluation.
Three studies have been conducted between 1971 and 1998 by the
EORTC CLG, in order to evaluate the type of consolidation therapy and
the type of maintenance therapy (EORTC study 58741), the use of less
aggressive regimen for low risk patients (EORTC study 58831), the
eﬃciency of high dose methotrexate to replace cranial radiotherapy for
sub-clinical central nervous system (CNS) involvement for medium or
high risk patients (EORTC study 58832) and the feasibility of a rapidly
rotating and intensive chemotherapy regimen for very high risk patients
[1–4] (EORTC study 58881) (see Table 1).
In order to avoid the sending of documents to the family of a de-
ceased patient, the vital status of all patients was ﬁrst updated (see
below, level 1). For identiﬁed survivors, an “Information sheet and
informed consent form”, a “Questionnaire on long-term outcome after
leukemia”, and QOL questionnaires were sent to the patients by the
institutions. Survivors were deﬁned as:
- Alive and agreeing to take part in case they sent back a completed
and signed informed consent;
- Alive and disagreeing to take part, by mail or by phone call;
- Lost to follow up in case their contact detail could not be retrieved,
or in case the institutions received no answer after two attempts.
For the information that had to be updated (e.g. disease status, late










































































































































































































































































































































































































































































































































































































C. Piette et al. Journal of Cancer Policy 15 (2018) 82–86
83
in four levels:
• Level 1 – Update of the vital status (alive, dead or lost to follow up,
date last known to be alive or date of death)
The update of the vital status was done directly by the in-
stitutions based on either their own medical records or on information
retrieved from the national registries at the institution's request.
• Level 2 – Collection of medical data
Medical data (disease status, late adverse eﬀects and SMN)
were retrieved by the institutions from the medical records of the pa-
tients and completed in the EORTC database by means of an electronic
“Outcome form”, speciﬁcally designed for the 58LAE project. The
Outcome form was pre-ﬁlled with the most recent data already avail-
able in the EORTC database, in order to reduce the workload and the
risk of mistakes for the institutions. New medical visit or com-
plementary examinations were recommended when feasible, but not
mandatory.
Late adverse eﬀects were deﬁned as adverse eﬀects occurring 2
months or later after ending ﬁrst line therapy or during the ﬁrst line
therapy period and persisting 2 months or more after ending ﬁrst line
therapy.
SMN was deﬁned as any malignancy that occurred after the
diagnosis of ALL and distinct from it, whatever the remission status of
the patient. Benign tumors were not considered as SMN, except for CNS
tumors.
• Level 3 – Collection of socioeconomic data from patients of 18 years
or older at the time of the study
These data (marital status, education, work, insurance, puberty,
fertility and oﬀspring) were collected from identiﬁed survivors by
means of a “Questionnaire on long-term outcome after leukemia”, de-
rived from the “Life Situation Questionnaire” developed by the EORTC
Lymphoma group [5].
• Level 4 – Collection of QOL data from patients of 18 years or older at
the time of the study
Three QOL questionnaires were used for this part of the project:
the “Short Form Health Survey” (SF-12) [6], the “Impact of Cancer-
Childhood Survivors” (IOC-CS) [7] and a qualitative instrument derived
from the “Quality of Life Systemic Inventory” (QLSI) [8].
3. The results
A total of 32 institutions in Belgium and France took part to levels 1
and 2 (vital status and medical data), and 22 institutions also partici-
pated in levels 3 and 4 (socioeconomic and QOL data).
A total of 3228 patients were included for ALL or lymphoblastic
lymphoma in EORTC CLG studies between 1971 and 1998, and 2621
were eligible in EORTC study 58LAE (update of vital status) (Fig. 1). A
total of 723 patients were alive, 507 were dead and 1391 were lost to
follow-up.
Medical, socioeconomic and QOL data were updated for respec-
tively 1676, 507, and 193 patients, representing 79%, 36% and 14% of
eligible patients (Table 2).
Diﬀerent sub-projects have been completed in the framework of the
EORTC study 58LAE.
The ﬁrst project evaluated the long-term prognostic and predictive
value of ETV6-RUNX1 in B-cell precursor (BCP)-ALL patients treated
according to EORTC studies 58881 and 58951 [9]. In childhood BCP-
ALL, the presence of an ETV6-RUNX1 fusion transcript deﬁnes one of
the most prevalent genetic subgroups, and has been associated with a
relatively high number of late relapses. Furthermore, although this al-
teration is associated with favourable outcome, several questions re-
lated to the therapeutic approach remained open. A long-term update of
the EORTC CLG results was therefore warranted. In our series, the
presence of ETV6-RUNX1 was associated with better outcome and with
virtually no relapse after 6 years from diagnosis. ETV6-RUNX1 positive
patients had speciﬁc sensitivities to treatments. They could beneﬁt from
dexamethasone during induction whereas maintenance therapy should
not be intensiﬁed. These results stressed the importance of analysing
homogeneous oncogenic subgroups when comparing diﬀerent ther-
apeutic schemes.
In the second sub-project, we investigated the long-term outcome,
the occurrence of SMN and the incidence of late toxicities in medium
and high risk patients, without CNS involvement, and randomized for
receiving or not cranial radiotherapy (CRT) in the EORTC study 58832
[10]. Historically, pre-emptive cranio-spinal or CRT was a standard
component of childhood ALL treatment protocols, to prevent CNS re-
lapses. Following the emergence of CRT-related sequellae (neurocog-
nitive, endocrine or SMN), intrathecal (IT) and systemic chemotherapy
successfully replaced CRT in most protocols for standard risk ALL.
However, in medium and high risk ALL patients its omission is still
debatable. A total of 176 randomized patients were included in the
analyses: 84 in the CRT group and 92 in the No CRT group. Omission of
CRT did not increase the risk of CNS or non-CNS relapse. On long-term
evaluation, CRT was associated with a higher incidence of SMN, late
CNS and endocrine toxicities. These long-term results indicate that
prophylactic CRT can be safely omitted in childhood medium and high
risk ALL patients receiving IT and systemic chemotherapy as CNS
prophylaxis.
The third sub-project assessed the long-term socioeconomic out-
comes of adult survivors of childhood ALL enrolled in the three EORTC
studies 58741, 58831/2 and 58881 and the eﬀect of patient’s and dis-
ease characteristics and treatment modalities [11]. Exposure to treat-
ments may have severe toxicities such as cognitive deterioration after
CRT and impaired general physical functioning after hematopoietic
stem cell transplantation (HSCT). These late eﬀects may negatively
impact the socioeconomic functioning of survivors. The median time
between the diagnosis and the socioeconomic evaluation was 20 years
(range: 13–42). The median age at follow-up was 25 years (range:
18–53). Among survivors at school at the time of the diagnosis, 22%
retook one and 6% two or more years due to the disease and 4% were
unable to ﬁnish their education. Interestingly, 21% of the survivors had
more and only 10% had less educational ambitions due to the disease.
More than a half of the survivors had at least a bachelor (under-
graduate) degree, 64% had a job and 38% were married or lived with
their partner. Among those 25 years of age or older, the percentages for
obtaining a bachelor degree, having a job and having a partner were
54%, 84% and 57%, respectively. In a multivariate model, HSCT and
CRT were associated with a higher probability of not obtaining a ba-
chelor degree and HSCT was associated with not having a job. Having a
relapse was associated with a higher probability of not having a partner
and working half-time. This study added to the body of evidence sup-
porting the omission of CRT when other treatment alternatives are
suﬃcient, like in ﬁrst line treatment. It also indicated the need to
provide special support to the most vulnerable groups of childhood ALL
survivors, in particular those who received HSCT.
Finally, we evaluated the fertility status of adult survivors of
childhood ALL enrolled in the three EORTC studies 58741, 58831/2
and 58881 [12]. The impact on fertility caused by widely employed
ALL treatments such as alkylating agents, cranial radiotherapy, total
body irradiation and orchiectomy has indeed been an emerging concern
over the last years. The median time between the diagnosis and the
evaluation was 20 years (range: 13–42). The median age at follow-up
was 25 years (range: 18–53). Among females who had tried to become
pregnant, 89% had been pregnant, 75% had children and 12% used
medical help to become pregnant. One ﬁfth of the ever-pregnant
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females had ever had a miscarriage. The incidences of other negative
pregnancy outcomes (e.g. birth defect, medical abortion) were low. The
average number of children females had was 0.36 (95% CI: 0.27–0.44).
Among males who had tried to have children, 83% made their partner
pregnant, 72% had children and 7% used medical help to make their
partner pregnant. For both females and males, the incidence of negative
pregnancy outcomes other than miscarriage was low.
4. The challenges
The global aim of assessing the long-term outcome of a large and
multinational cohort of patients is as necessary, as it is arduous. The
EORTC study 58LAE is an ambitious, far-reaching project, and as such,
it has raised several challenges when translating the initial study design
into the “real-life” setting.
Firstly, there is an inherent diﬃculty in studies that require a
prolonged follow-up of patients. In childhood cancer, there is an ad-
ditional diﬃculty to track down the steps of the patients, being the
transition from children or adolescent and young adults (AYA) units
and hospitals to adult oncology facilities a critical point, in which there
is a high risk of losing subjects to follow-up. Not only the change of the
caregivers’ team, but also the natural change of contact details over
time, add to the complexity of survivorship studies. Depending on the
personal data protection regulation of each country, it is sometimes
diﬃcult to access these contact details. Furthermore, the lack of social
security numbers in children impairs traceability when they become
adults.
Secondly, the inclusion of patients from multiple clinical trials also
complicates the statistical analysis of the association between treatment
exposures and long-term health eﬀects. A large variety of treatment
protocols makes it diﬃcult to distinguish between the eﬀects of speciﬁc





























Fig. 1. CONSORT diagram for EORTC study 58LAE.
Table 2
Number of available data in the EORTC database for levels 1 (vital status), 2 (medical data), 3 (socioeconomic outcome) and 4 (QOL).
58LAE study levels Number of participating institutions Number of eligible
patients
Number of available data in the EORTC database (% eligible patients)
58741 58831/2 58881 Total
Level 2: medical data 32 2114 77 (95.1) 439 (80.1) 1160 (78.1) 1676 (79.3)
Level 3: socioeconomic outcome 22 1420 25 (43.9) 109 (30.9) 373 (36.9) 507 (35.7)
Level 4: QOL 22 1420 17 (29.8) 42 (11.9) 134 (13.3) 193 (13.6)
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other in terms of the period of time when they were performed or other
characteristics such as the inclusion criteria of the patients. These dif-
ferences may introduce confounding that may be diﬃcult to account
for. For example, the eﬀect of treatment strategies used more frequently
in older trials, like cranial radiotherapy, is confounded by the eﬀect of
the age of cancer survivors at the time of the assessment of long-term
outcomes.
Thirdly, in order to perform a comprehensive and updated cross-
sectional assessment of the health and quality of life of a survivors
cohort, diﬀerent approaches or a combination of them can be im-
plemented for data collection. This may vastly increase the funding
requirements and adds to the complexity of carrying out long-term
outcome studies. Some of these possibilities to gather updated patient
information include:
Patient self-reported clinical outcomes, which are easier to access
but can lead to incomplete or misleading data;
Medical records, which are certainly more reliable but not always
updated;
New clinical and complimentary examinations, which can be too
expensive and logistically not feasible for the participating institutions
to organize; and
Contacting the general practitioners, which can be problematic from
a regulatory and administrative point of view, as explained in the next
paragraph.
Fourthly, overcoming the heavy healthcare administrative ma-
chinery is certainly a signiﬁcant challenge. This is more so the case
when attempting to gather patient information from the pre-compu-
terization era; old paper medical records are diﬃcult to retrieve from
archives. Another aspect of the administrative barriers that need to be
dealt with is that data transfer from national registries cannot be cen-
tralized by the clinical research organization and must be done instead
through the participating institutions. This slows down all study-related
procedures, increasing the complexity and the need for resources.
Finally, the patient informed consent of old studies does frequently
not foresee new data collection. This shortage is being addressed in the
more recent and current studies, and will facilitate future survivorship
studies, but it entails additional diﬃculties for the present ones.
However, it is noteworthy that in spite of the high number of patients
lost to follow-up, the number of contacted patients refusing to partici-
pate is very low, which highlights the weight of administrative and
regulatory obstacles over the willingness of participants.
Overall, conducting a long-term outcome study is unquestionably as
enriching and rewarding, as it is full of challenges.
5. The perspectives
With all the above-explained challenges, new ways of addressing
survivorship studies are needed. We have already implemented a novel
and multi-angle approach to help collect survivors’ data and draw a
comprehensive picture of their health and well-being. We have re-
trieved data from both the healthcare providers and institutions,
through medical records and new outcome forms; and from the pa-
tients, through socioeconomic and QOL questionnaires.
In addition to this, we are currently evaluating other possibilities for
data collection, both for socioeconomic and medical outcomes, through
collaborations with national and European cancer registries and ad-
ministrative databases. Particularly the perspective of cross-matching
both sources of information could be a powerful tool to enhance not
only the quantity, but also the quality of the data.
Moreover, we hope for a paradigm shift when approaching long-
term follow-up of patients. This should no longer be seen as a merely
complimentary, even optional aspect of cancer research, but rather as
an essential part of clinical trials. This will allow for prospectively
planned follow-up strategies, which will certainly improve survivorship
studies.
Lastly, worth mentioning are the new possibilities that the digital
era has to oﬀer. The use of phone/table apps is already being im-
plemented in the QOL assessment of ongoing clinical trials. It is only a
matter of time until these tools become a regular part of daily clinical
practice; they might as well be used for long-term follow-up of patients,
which would certainly facilitate and improve the quality of survivorship
studies.
The importance of non-interrupted follow-up of cancer survivors
throughout their life transitions from childhood to adolescence and
adulthood is being increasingly recognized by the diﬀerent healthcare
research stakeholders as being of high importance. It is time to address
this need and translate it into aﬀordable and well-planned long-term
follow-ups in the context of clinical trials.
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